ラボのトピックス | 東北大学大学院医学系研究科・加藤研究室

再生・細胞医療・遺伝子治療実現加速化プログラム
（再生・細胞医療・遺伝子治療研究開発課題（基礎応用研究課題））

再生医療（AMED）
分担研究者：東北大学　加藤幸成（代表：京都大学　金子新）
令和５年度〜令和７年度
課題名：GPC3 CAR 発現 iPS 細胞由来 ILC/NK 細胞の患者体内生存延長と抗腫瘍エフェクター機能向上を目指したリバーストランスレーショナル研究

東北大学ではこれまで、がん細胞に特異的な反応性を示すモノクローナル抗体の作製法（CasMab法）を用いることにより、ポドプラニンに対して、複数のCasMabの作製に成功した。ポドプラニンはリンパ管内皮細胞、肺胞上皮細胞、皮膚基底細胞、腎上皮細胞などの全身の正常細胞に高発現し、通常の抗体では様々な副作用が懸念される。CasMabはそれらの正常細胞に反応せず、肺がん、食道がん、悪性中皮腫、悪性脳腫瘍、卵巣がんなどの複数の難治性がんに高い反応性を示すため、抗体医薬の新規ターゲットとして期待される。さらに、乳がんや膵がんの他に血管内皮細胞などの正常細胞にも高発現しているポドカリキシンに対しても、がん特異的な反応性を示すCasMabを複数作製してきた。本プロジェクトにおいては、京都大学が保有するがん特異的抗体をヒト化あるいはscFv化し、CAR-Tに搭載できるフォーマットへの最適化を行う。
＜文献＞
23bm1123027h0001

2024

28. Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y.
A Cancer-Specific anti-Podoplanin Monoclonal Antibody, PMab-117-mG2a Exerted Antitumor Activities in Human Tumor Xenograft Models
Cells, 13(22), 1833; https://doi.org/10.3390/cells13221833, 2024 (PDF; preprint)

27. Hirose M, Suzuki H, Ubukata R, Tanaka T, Kaneko MK, Kato Y.
Development of specific anti-mouse atypical chemokine receptor 4 monoclonal antibodies
Biochem Biophys Rep, 40, 101824, https://doi.org/10.1016/j.bbrep.2024.101824, 2024 (PDF; preprint)

26. Ishikawa K, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Li G, Tanaka T, Kawada M, Kaneko MK, Ohkoshi A, Katori Y, Kato Y.
Antitumor activities of defucosylated anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer
Oncology reports, 52(5), 147, https://doi.org/10.3892/or.2024.8806, (PDF; preprint)

25. Ishikawa K, Suzuki H, Ohishi T, Li G, Tanaka T, Kawada M, Ohkoshi A, Kaneko MK, Katori Y, Kato Y.
Anti-CD44 variant 10 monoclonal antibody exerts antitumor activity in mouse xenograft models of oral squamous cell carcinomas
Int. J. Mol. Sci., 25(17), 9190; https://doi.org/10.3390/ijms25179190, 2024 (PDF; preprint)

24. Ubukata R, Suzuki H, Tanaka T, Li G, Kaneko MK, Kato Y.
Development of Sensitive Anti-Mouse CCR5 Monoclonal Antibodies using the N-terminal peptide immunization
Monoclon. Antib. Immunodiagn. Immunother., 43(4), 112-118, https://doi.org/10.1089/mab.2024.0009, 2024 (PDF)

23. Suzuki H, Tanaka T, Li G, Ouchida T, Kaneko MK, Kato Y.
Development of a Sensitive Anti-Mouse CCR5 Monoclonal Antibody for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 43(4), 96-100, https://doi.org/10.1089/mab.2024.0004, 2024 (PDF; preprint)

22. Kobayashi H, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Mouse CCR8 Monoclonal Antibody C8Mab-2 using flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 43(4), 101-107, https://doi.org/10.1089/mab.2024.0002, 2024 (PDF; preprint)

21. Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Kato Y.
Anti‐HER2 cancer‐specific mAb, H2Mab‐250‐hG1 possesses higher complement‐dependent cytotoxicity than trastuzumab
Int. J. Mol. Sci., 25(15), 8386; https://doi.org/10.3390/ijms25158386, 2024 (PDF; preprint)

20. Arimori T, Mihara E, Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Takagi J, Kato Y.
Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies
Structure, 32(5),536-549, https://doi.org/10.1016/j.str.2024.02.007, 2024 (PDF)

19. Li G, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Cx1Mab-1: A Novel Anti-mouse CXCR1 Monoclonal Antibody for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 59-66, DOI: 10.20944/preprints202311.0501.v2, 2023 (PDF;preprint)

18. Ouchida T, Li G, Suzuki H, Yanaka M, Nakamura T, Handa S, Tanaka T, Kaneko MK, Kato Y.
PMab-314: An Anti-Giant Panda Podoplanin Monoclonal Antibody
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 53-58, doi:10.1089/mab.2024.0003, 2024 (PDF)

17. Kaneko MK, Suzuki H, Kato Y.
Establishment of a novel cancer-specific anti-HER2 monoclonal antibody H2Mab-250/H2CasMab-2 for breast cancers
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 35-43, DOI: 10.1089/mab.2023.0033, 2024 (PDF;online;preprint)

16. Ouchida T, Isoda Y, Nakamura T, Yanaka M, Tanaka T, Handa S, Kaneko MK, Suzuki H, Kato Y.
Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C1Mab-6
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 67-74, https://doi.org/10.1089/mab.2023.0032, 2024 (PDF;preprint)

15. Okada Y, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody using PA Scanning and RIEDL Scanning
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 44-52, https://doi.org/10.1089/mab.2023.0029, 2024 (PDF;preprint)

14. Inoue T, Yamamoto Y, Sato K, Nakamura Y, Shimizu Y, Ogawa M, Onodera T, Takahashi Y, Wakita T, Kaneko MK, Fukasawa M, Kato Y, Noguchi K.
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
iScience,27(4),109363, DOI:https://doi.org/10.1016/j.isci.2024.109363, 2024 (PDF)

13. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Establishment of anti-dog PD-L1 monoclonal antibodies for immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., 43(1), 17–23, https://doi.org/10.1089/mab.2023.0014, 2024 (PDF; preprint)

12. Okada Y, Suzuki H, Kaneko MK, Kato Y.
Development of a Sensitive Anti-Mouse CD39 Monoclonal Antibody (C39Mab-1) for Flow Cytometry and Western Blot Anal-yses
Monoclon. Antib. Immunodiagn. Immunother., 43(1), 24–31, https://doi.org/10.1089/mab.2023.0016, 2024 (PDF; preprint)

11. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Cx4Mab-1: a Novel Anti-mouse CXCR4 Monoclonal Antibody for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 43(1), 10–16, DOI: 10.1089/mab.2023.0023, 2024 (PDF;preprint)

10. Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Tanaka T, Kato Y.
A Cancer-specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models
Int. J. Mol. Sci., 25(3), 1941; https://doi.org/10.3390/ijms25031941, 2024 (PDF)

9. Tanaka T, Suzuki H, Ohishi T, Kaneko MK, Kato Y.
Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab-77-mG2a-f
Cancer Sci., 115(1), 298-309, https://doi.org/10.1111/cas.16008, 2024 (PDF; preprint)

8. Suzuki H, Ohishi T, Tanaka T Kaneko MK, Kato Y.
A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts
Int. J. Mol. Sci., 25, 161. https://doi.org/10.3390/ijms25010161, 2024 (PDF; preprint)

2023

7. Isoda Y, Kaneko MK, Tanaka T, Suzuki H, Kato Y.
Epitope Mapping of an Anti-Ferret Podoplanin Monoclonal Antibody using the PA Tag-Substituted Analysis
Monoclon. Antib. Immunodiagn. Immunother., 42(6), 189–193, DOI: 10.1089/mab.2023.0026, 2023 (PDF; preprint)

6. Ouchida T, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
PMab-301: An Anti-Giraffe Podoplanin Monoclonal Antibody for Immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., 42(6), 209–215, https://doi.org/10.1089/mab.2023.0020, 2023 (PDF; preprint)

5. Suzuki H, Tanaka T, Kudo Y, Tawara M, Hirayama A, Kaneko MK, Kato Y.
A Rat Anti-Mouse CD39 Monoclonal Antibody for flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 42(6), 203–208, DOI: 10.1089/mab.2023.0018, 2023 (PDF; preprint)

4. Nanamiya R, Suzuki H, Kaneko MK, Kato Y.
Development of an Anti−EphB4 Monoclonal Antibody for Multiple Applications against Breast Cancers
Monoclon. Antib. Immunodiagn. Immunother.,42(5), 153–156, https://doi.org/10.1089/mab.2023.0015, 2023 (PDF; preprint)

3. Suzuki H, Ohishi T, Kaneko MK, Kato Y.
Humanized and defucosylated antibody against Podoplanin (humLpMab-23-f) exerted antitumor activities in human tumor xenograft models
Cancers, 15(20), 5080; https://doi.org/10.3390/cancers15205080, 2023 (PDF)

2. Suzuki H, Ohishi T, Nanamiya R, Kawada M, Kaneko MK, Kato Y.
Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2
Curr. Issues Mol. Biol., 45(10), 7734-7748; https://doi.org/10.3390/cimb45100488, 2023　(PDF)

1. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry
Int. J. Transl. Med., 3(3), 310-320; 2023 (PDF)

再生医療実現拠点ネットワークプログラム
（疾患・組織別実用化研究拠点（拠点Ｃ））

再生医療（AMED）
分担研究者：東北大学　加藤幸成（代表：京都大学　金子新）
令和２年度（9月1日）〜令和４年度
課題名：次世代型ヒト人工染色体ベクターによるCAR交換型高機能再生T細胞治療の開発拠点

東北大学ではこれまで、がん細胞に特異的な反応性を示すモノクローナル抗体の作製法（CasMab法）を用いることにより、ポドプラニンに対して、複数のCasMabの作製に成功した。ポドプラニンはリンパ管内皮細胞、肺胞上皮細胞、皮膚基底細胞、腎上皮細胞などの全身の正常細胞に高発現し、通常の抗体では様々な副作用が懸念される。CasMabはそれらの正常細胞に反応せず、肺がん、食道がん、悪性中皮腫、悪性脳腫瘍、卵巣がんなどの複数の難治性がんに高い反応性を示すため、抗体医薬の新規ターゲットとして期待される。さらに、乳がんや膵がんの他に血管内皮細胞などの正常細胞にも高発現しているポドカリキシンに対しても、がん特異的な反応性を示すCasMabを複数作製してきた。本プロジェクトにおいては、ポドプラニンやポドカリキシンに対するCasMabをヒト化あるいはscFv化し、CAR-Tに搭載できるフォーマットへの最適化を行う。　
＜文献＞

2023

44. Suzuki H, Ohishi T, Nanamiya R, Kawada M, Kaneko MK, Kato Y.
Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2
Curr. Issues Mol. Biol., 45(10), 7734-7748; https://doi.org/10.3390/cimb45100488, 2023　(PDF)

43. Suzuki H, Goto N, Tanaka T, Ouchida T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas
antibodies, 12(3), 45; https://doi.org/10.3390/antib12030045, 2023 (PDF)

42. Suzuki H, Kitamura K, Goto N, Ishikawa K, Ouchida T, Tanaka T, Kaneko MK, Kato Y.
A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 was Established for Multiple Applications
Int. J. Mol. Sci., 24(9), 8411; https://doi.org/10.3390/ijms24098411, 2023 (PDF)

41. Kudo Y, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas
antibodies, 12(2), 31, https://doi.org/10.3390/antib12020031, 2023 (PDF)

40. Isoda Y, Tanaka Y, Suzuki H, Asano T, Kitamura K, Kudo Y, Ejima R, Ozawa K, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of the Novel Anti-human CCR9 Monoclonal Antibody (C9Mab-11) by 2 × Alanine Scanning
Monoclon. Antib. Immunodiagn. Immunother., 42(2), 73–76, https://doi.org/10.1089/mab.2022.0035, 2023 (PDF)

39. Tateyama N, Asano T, Tanaka T, Isoda T, Okada Y, Kobayashi H, Li G, Nanamiya R, Yoshikawa T, Kaneko MK, Suzuki H, Kato Y.
Epitope Mapping of Anti-mouse CCR3 Monoclonal Antibodies (C3Mab-6 and C3Mab-7)
Monoclon. Antib. Immunodiagn. Immunother., 42(2), 68–72, https://doi.org/10.1089/mab.2022.0034, 2023 (PDF)

38. Suzuki H, Ozawa K, Tanaka T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody C44Mab-34 for Multiple Applications against Oral Carcinomas
Biomedicines, 11(4), 1099; https://doi.org/10.3390/biomedicines11041099, 2023 (PDF)

37. Li G, Suzuki H, Tanaka T, Asano T, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-EpCAM Monoclonal Antibody (EpMab-37) using the Alanine Scanning Method
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 41–47, doi: 10.1089/mab.2022.0031, 2023 (PDF)

36. Kobayashi H, Asano T, Suzuki H, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y.
Establishment of a Sensitive Monoclonal Antibody against Mouse CCR9 (C9Mab-24) for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 15–21, https://doi.org/10.1089/mab.2022.0032, 2022 (PDF)

35. Nanamiya R, Ohishi T, Suzuki H, Mizuno T, Yoshikawa T, Asano T, Tanaka T, Kaneko MK, Kato Y.
Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody (H77Bf) exerts antitumor activities in mouse xenograft models of canine osteosarcoma
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 27–33, doi:10.1089/mab.2022.0022, 2022 (PDF)

34. Suzuki H, Asano T, Ohishi T, Yoshikawa T, Suzuki H, Mizuno T, Tanaka T, Kawada M, Kaneko MK, Kato Y.
Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf)
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 34–40, doi: 10.1089/mab.2022.0023, 2022 (PDF)

33. Isoda Y, Tanaka T, Suzuki H, Asano T, Yoshikawa T, Kitamura K, Kudo Y, Ejima R, Ozawa K, Kaneko MK, Kato Y.
Epitope Mapping using the Cell-Based 2×Alanine Substitution Method about the Anti-mouse CXCR6 Monoclonal Antibody, Cx6Mab-1
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 22–26, doi: 10.1089/mab.2022.0029, 2022 (PDF)

32. Suzuki H, Tanaka T, Goto N, Kaneko MK, Kato Y.
Development of a novel anti-CD44 variant 4 monoclonal antibody C44Mab-108 for immunohistochemistry
Curr. Issues Mol. Biol., 45(3), 1875-1888; https://doi.org/10.3390/cimb45030121, 2023 (PDF)

31. Ejima R, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 variant 6 Monoclonal Antibody C44Mab-9 for Multiple Applications against Colorectal Carcinomas
Int. J. Mol. Sci., 24(4), 4007; https://doi.org/10.3390/ijms24044007, 2023 (PDF)

30. Kobayashi H, Asano T, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Determination of the Binding Epitope of an Anti-mouse CCR9 Monoclonal Antibody (C9Mab-24) using the 1 × alanine and 2 × alanine-substitution Method
antibodies, 12(1), 11; https://doi.org/10.3390/antib12010011, 2023 (PDF)

29. Li G, Suzuki H, Ohishi T, Asano T, Tanaka T, Yanaka M, Nakamura T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Antitumor activities by a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models
Int J Mol Med, 51(2), 18, https://doi.org/10.3892/ijmm.2023.5221, 2023 (PDF)

28. Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M.
Current targeted therapy for metastatic colorectal cancer
Int. J. Mol. Sci. , 24(2), 1702; https://doi.org/10.3390/ijms24021702, 2023 (PDF)

2022

27. Asano T, Tanaka T, Suzuki H, Li G, Nanamiya R, Tateyama N, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Development of a Novel Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) by N-Terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 343–349, doi: 10.1089/mab.2022.0021, 2022 (PDF)

26. Tanaka T, Suzuki H, Asano T, Li G, Nanamiya R, Tateyama N, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Epitope mapping of an Anti-Mouse CCR2 Monoclonal Antibody (C2Mab-6) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 339–342, doi:10.1089/mab.2022.0020, 2022 (PDF)

25. Saito M, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow cytometry and Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 333–338, https://doi.org/10.1089/mab.2021.0069, 2022 (PDF)

24. Kawabata H, Ohishi T, Suzuki H, Asano T, Kawada M, Suzuki H, Kaneko MK, Kato Y.
A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 320–327, https://doi.org/10.1089/mab.2021.0049, 2022 (PDF)

23. Nanamiya R, Suzuki H, Takei J, Li G, Goto N, Harada H, Saito M, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of Monoclonal Antibody 281-mG2a-f Against Golden Hamster Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 311–319, https://doi.org/10.1089/mab.2021.0058, 2022 (PDF)

22. Tanaka T, Suzuki H, Isoda Y, Asano T, Nakamura T, Yanaka M, Handa S, Takahashi N, Okuno S, Yoshikawa T, Li G, Nanamiya R, Goto N, Tateyama N, Okada Y, Kobayashi H, Kaneko MK, Kato Y.
Development of a Sensitive Anti-human CCR9 Monoclonal Antibody (C9Mab-11) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 303–310, doi: 10.1089/mab.2022.0027, 2022 (PDF)

21. Tateyama N, Asano T, Suzuki H, Li G, Yoshikawa T, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of Anti-mouse CCR3 Monoclonal Antibodies using Flow Cytometry
antibodies, 11(4), 75; https://doi.org/10.3390/antib11040075, 2022 (PDF)

20. Asano T, Tanaka T, Suzuki H, Li G, Ohishi T, Kawada M, Yoshikawa T, Kaneko MK, Kato Y.
A Defucosylated Anti-EpCAM Monoclonal Antibody (Ep-Mab-37-mG2a-f) Exerts Antitumor Activity in Xenograft Model
antibodies, 11(4), 74; https://doi.org/10.3390/antib11040074, 2022 (PDF)

19. Tateyama N, Suzuki H, Ohishi T, Asano T, Tanaka T, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Antitumor Activity of an anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
pharmaceutics,14(11), 2494; https://doi.org/10.3390/pharmaceutics14112494, 2022 (PDF)

18. Isoda Y, Tanaka T, Suzuki H, Asano T, Nakamura T, Yanaka M, Handa S, Komatsu Y, Okuno S, Takahashi N, Okada Y, Kobayashi H, Li G, Nanamiya R, Goto N, Tateyama N, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-mouse CXCR6 Monoclonal Antibody (Cx6Mab-1) using the 2×Alanine scanning method
Monoclon. Antib. Immunodiagn. Immunother.,41(5),275–278, DOI: 10.1089/mab.2022.0019, 2022 (PDF)

17. Tanaka T, Suzuki H, Li G, Nanamiya R, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody (K036C2)
Monoclon. Antib. Immunodiagn. Immunother.,41(5),285–289, DOI: 10.1089/mab.2022.0018, 2022 (PDF)

16. Saito M, Suzuki H, Asano T, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y.
KLMab-1: An Anti-Human KLRG1 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother.,41(5),279–284, https://doi.org/10.1089/mab.2022.0016, 2022 (PDF)

15. Ishikawa A, Waseda M, Ishii T, Kaneko MK, Kato Y, Kaneko S.
Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in animal model
Genes Cells,27(9), 549-558, https://doi.org/10.1111/gtc.12972, 2022 (PDF)

14. Tanaka T, Li G, Saito M, Suzuki H, Asano T, Kaneko MK, Kato Y.
Development of an Anti-human CCR2 Monoclonal Antibody (C2Mab-9) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 188–193, https://doi.org/10.1089/mab.2022.0001, 2022 (PDF)

13. Kudo Y, Suzuki H, Kaneko MK, Kato Y.
Development of a Monoclonal Antibody PMab-295 Against Elephant Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 194–201, https://doi.org/10.1089/mab.2022.0007, 2022 (PDF)

12. Asano T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Identification of the Binding Epitope of an Anti-Mouse CCR4 Monoclonal Antibody, C4Mab-1
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 214–220, https://doi.org/10.1089/mab.2022.0015, 2022 (PDF)

11. Okada Y, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Elephant Podoplanin Monoclonal Antibody (PMab-295) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 221–227, https://doi.org/10.1089/mab.2022.0017, 2022 (PDF)

10. Suzuki H, Ohishi T, Asano T, Tanaka T, Saito M, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors
Oncol. Rep.,,48(3), 154, https://doi.org/10.3892/or.2022.8366, 2022 (PDF)

9. Saito M, Suzuki H, Kaneko MK, Kato Y.
TgMab-2: An Anti-Human TIGIT Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 157–162, https://doi.org/10.1089/mab.2022.0013, 2022 (PDF)

8. Tanaka T, Li G, Asano T, Kaneko MK, Suzuki H, Kato Y.
Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody C2Mab-9
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 150–156, https://doi.org/10.1089/mab.2022.0012, 2022 (PDF)

7. Goto N, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Chinese/golden Hamster Podoplanin Monoclonal Antibody
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 163–169, https://doi.org/10.1089/mab.2022.0014, 2022 (PDF)

6. Kitamura K, Suzuki H, Kaneko MK, Kato Y.
Cx6Mab-1: a Novel Anti-mouse CXCR6 Monoclonal Antibody established by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 133–141, https://doi.org/10.1089/mab.2022.0010, 2022 (PDF)

5. Li G, Suzuki H, Asano T, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Development of A Novel Anti-EpCAM Monoclonal Antibody for Various Applications
Antibodies, 11(2), 41; https://doi.org/10.3390/antib11020041, 2022 (PDF) (Preprint)

4. Goto N, Suzuki H, Tanaka T, Asano T, Kaneko MK, Kato Y.
Development of a novel anti-CD44 monoclonal antibody for multiple applications against esophageal squamous cell carcinomas
Int. J. Mol. Sci., 23(10), 5535; https://doi.org/10.3390/ijms23105535, 2022 (PDF) (Preprint)

2021

3. Asano　T, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of a Cancer-specific Anti-podocalyxin Monoclonal Antibody (PcMab-60) using Enzyme-linked Immunosorbent Assay and Surface Plasmon Resonance
Monoclon. Antib. Immunodiagn. Immunother., DOI: 10.1089/mab.2021.0030, 2021 (ref)
(ポドカリキシンに対するがん特異的抗体のエピトープ解析)

2020

2. Kaneko MK, Ohishi T, Kawada M, Kato Y.
A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma
Biochem Biophys Rep., 24, 100826, https://doi.org/10.1016/j.bbrep.2020.100826, 2020 (PDF)
(ポドカリキシンに対するがん特異的抗体の開発)

1. Kaneko MK, Ohishi T, Nakamura T, Inoue H, Takei J, Sano M, Asano T, Sayama Y, Hosono H, Suzuki H, Kawada M, Kato Y.*
(*corresponding author)
Development of Core-fucose Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies
Monoclon. Antib. Immunodiagn. Immunother., 39(5), 167–174, https://doi.org/10.1089/mab.2020.0019, 2020 (PDF)
(ポドプラニンに対するヒト化抗体の開発)

再生・細胞医療・遺伝子治療実現加速化プログラム
（再生・細胞医療・遺伝子治療研究開発課題（基礎応用研究課題））

動画(YouTube)

総説(pdf)

AMED project

再生医療実現拠点ネットワークプログラム
（疾患・組織別実用化研究拠点（拠点Ｃ））

動画(YouTube)

総説(pdf)

AMED project

再生・細胞医療・遺伝子治療実現加速化プログラム （再生・細胞医療・遺伝子治療研究開発課題（基礎応用研究課題））

動画(YouTube)

総説(pdf)

AMED project

再生医療実現拠点ネットワークプログラム （疾患・組織別実用化研究拠点（拠点Ｃ））

動画(YouTube)

総説(pdf)

AMED project

再生・細胞医療・遺伝子治療実現加速化プログラム
（再生・細胞医療・遺伝子治療研究開発課題（基礎応用研究課題））

再生医療実現拠点ネットワークプログラム
（疾患・組織別実用化研究拠点（拠点Ｃ））